Mihai Burai-Patrascu

Here to help: Molecular Forecaster Inc. (MFI) is a Research-as-a-Service company advancing and accelerating small molecule drug discovery. MFI walks alongside organizations as they navigate the unpredictable landscape of preclinical research. Targeting better research outcomes, we apply our knowledge and technology to create more certainty in hit discovery, hit-to-lead, and lead optimization. Why us: At MFI, we help startups, biotechs and pharmas de-risk early drug design by providing both the expertise and technology needed to make better decisions faster. Our value lies not just in tools, but in partnerships that move programs forward. Our diverse team of scientists guides molecule selection, optimization, and testing—maximizing the likelihood of program success. Put in a different way, we translate data into insight, and insight into smarter, faster decisions. No hype: Created out of 15 years of research at McGill University, and part of the inaugural Accelerate Quebec Program within the adMare Bioinnovations Center in Montréal, MFI has been evolving since 2019 into the service provider we are today. When clients choose MFI, they know we are partners, whether we are providing CADD (computer-aided drug design) capability and capacity, research consultation, or even novel software applications and functions. Our track record speaks for itself (https://molecularforecaster.com/testimonials/). Our tech: Rooted in chemistry and validated through real-world collaborations, our world-class drug discovery platform Forecaster supports diverse and complex therapeutic areas. Its specialized capabilities—ranging from nucleic acid modeling and covalent docking to metalloenzyme targeting and chemical library design—are supported by peer-reviewed publications in high impact journals . Our tools are not just theoretical—they’ve led to the discovery of novel, potent, and selective binders for targets including GPCRs, enzymes, RNA, and transcription factors. With proprietary algorithms protected as trade secrets, our platform provides partners with not only differentiated technology, but a strategic advantage. \*\* We do not mandate IP transfer in our agreements. \*\*